Data Sheet (Cat.No.T15616)

TargetMol

JNJ-10198409

Chemical Properties



CAS No. :	627518-40-5
Formula:	C18H16FN3O2
Molecular Weight:	325.34
Storage:	Powder: -20°C for 3 years | In solvent: -80°C for 1 year Actual storage temperature shall be subject to the COA.

Biological Description

Description	JNJ- 10198409 is a relatively selective and ATP competitive PDGF-RTK inhibitor (IC50=2 nM). JNJ-10198409 has good activity against PDGFR-β kinase (IC50=4.2 nM) and PDGFR-α kinase (IC50=45 nM). It is a dual-mechanism, antiangiogenic, and tumor cell antiproliferative agent.
Targets(IC50)	PDGFR
In vitro	JNJ-10198409 has effective antiproliferative activity in six of eight human tumor cell lines (IC50<0.033 μM). It also is a potent inhibitor of the c-Abl kinase (IC50: 22 nM) [1,2].

Solubility Information

Solubility	DMSO: 83.33 mg/mL (256.13 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 3.3 mg/mL (10.14 mM),Sonication is recommended. *Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.*

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	3.0737 mL	15.3685 mL	30.7371 mL
5 mM	0.6147 mL	3.0737 mL	6.1474 mL
10 mM	0.3074 mL	1.5369 mL	3.0737 mL
50 mM	0.0615 mL	0.3074 mL	0.6147 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

D'Andrea MR, et al. Validation of in vivo pharmacodynamic activity of a novel PDGF receptor tyrosine kinase inhibitor using immunohistochemistry and quantitative image analysis. Mol Cancer Ther. 2005 Aug;4(8):1198-204.
Ho CY, et al. (6,7-Dimethoxy-2,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenylamines: platelet-derived growth factor receptor tyrosine kinase inhibitors with broad antiproliferative activity against tumor cells. J Med Chem. 2005 Dec 29;48(26):8163-73.